Esperion Therapeutics (LTS:0IIM) Receivables Turnover : 0.93 (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Esperion Therapeutics Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Esperion Therapeutics's Revenue for the three months ended in Dec. 2024 was $69.1 Mil. Esperion Therapeutics's average Accounts Receivable for the three months ended in Dec. 2024 was $74.0 Mil. Hence, Esperion Therapeutics's Receivables Turnover for the three months ended in Dec. 2024 was 0.93.

Esperion Therapeutics Receivables Turnover Historical Data

The historical data trend for Esperion Therapeutics's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Esperion Therapeutics Receivables Turnover Chart

Esperion Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Receivables Turnover

Get a 7-Day Free Trial

18.37

4.44

2.66

2.83

5.17

Esperion Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Receivables Turnover	Get a 7-Day Free Trial															2.67	1.28	0.81	0.93	0.81

Competitive Comparison of Esperion Therapeutics's Receivables Turnover

For the Drug Manufacturers - Specialty & Generic subindustry, Esperion Therapeutics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Esperion Therapeutics's Receivables Turnover Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Esperion Therapeutics's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Esperion Therapeutics's Receivables Turnover falls into.

Save Embed

;

Save Embed

;

Esperion Therapeutics Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Esperion Therapeutics's Receivables Turnover for the fiscal year that ended in Dec. 2024 is calculated as

	Receivables Turnover (A: Dec. 2024 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2024 )	/ (	(Accounts Receivable (A: Dec. 2023 )	+	Accounts Receivable (A: Dec. 2024 ))	/	count )
=	332.314	/ (	(48.494	+	80.142)	/	2 )
=	332.314	/	64.318
=	5.17

Esperion Therapeutics's Receivables Turnover for the quarter that ended in Dec. 2024 is calculated as

	Receivables Turnover (Q: Dec. 2024 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Dec. 2024 )	/ (	(Accounts Receivable (Q: Sep. 2024 )	+	Accounts Receivable (Q: Dec. 2024 ))	/	count )
=	69.113	/ (	(67.824	+	80.142)	/	2 )
=	69.113	/	73.983
=	0.93

Esperion Therapeutics (LTS:0IIM) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Esperion Therapeutics Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Esperion Therapeutics's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Esperion Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Esperion Therapeutics Inc (LTS:0IIM) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

ESPR:USA 0ET:Germany 0ET:Germany

Address

3891 Ranchero Drive, Suite 150, Ann Arbor, MI, USA, 48108

Website

https://www.esperion.com

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Esperion Therapeutics Headlines

No Headlines